329 related articles for article (PubMed ID: 26948317)
1. Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.
Hong Q; Ma ZC; Huang H; Wang YG; Tan HL; Xiao CR; Liang QD; Zhang HT; Gao Y
Eur J Pharmacol; 2016 Apr; 777():1-8. PubMed ID: 26948317
[TBL] [Abstract][Full Text] [Related]
2. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet effects of caffeic acid due to Ca(2＋) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation.
Lee DH; Kim HH; Cho HJ; Bae JS; Yu YB; Park HJ
J Atheroscler Thromb; 2014; 21(1):23-37. PubMed ID: 24088646
[TBL] [Abstract][Full Text] [Related]
4. Aspirin eugenol ester inhibits agonist-induced platelet aggregation in vitro by regulating PI3K/Akt, MAPK and Sirt 1/CD40L pathways.
Shen DS; Yang YJ; Kong XJ; Ma N; Liu XW; Li SH; Jiao ZH; Qin Z; Huang MZ; Li JY
Eur J Pharmacol; 2019 Jun; 852():1-13. PubMed ID: 30797789
[TBL] [Abstract][Full Text] [Related]
5. Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation.
Endale M; Lee WM; Kamruzzaman SM; Kim SD; Park JY; Park MH; Park TY; Park HJ; Cho JY; Rhee MH
Br J Pharmacol; 2012 Sep; 167(1):109-27. PubMed ID: 22471932
[TBL] [Abstract][Full Text] [Related]
6. p-Terphenyl curtisian E inhibits in vitro platelet aggregation via cAMP elevation and VASP phosphorylation.
Kamruzzaman SM; Yayeh T; Ji HD; Park JY; Kwon YS; Lee IK; Kim S; Oh SH; Kim SD; Roh SS; Yun BS; Rhee MH
Vascul Pharmacol; 2013; 59(3-4):83-9. PubMed ID: 23872194
[TBL] [Abstract][Full Text] [Related]
7. The novel compound MP407 inhibits platelet aggregation through cyclic AMP-dependent processes.
Lin CS; Chen TH; Lin IH; Lee AR; Chou TC
Eur J Pharmacol; 2017 Nov; 815():324-331. PubMed ID: 28939294
[TBL] [Abstract][Full Text] [Related]
8. Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling.
Irfan M; Jeong D; Kwon HW; Shin JH; Park SJ; Kwak D; Kim TH; Lee DH; Park HJ; Rhee MH
Vascul Pharmacol; 2018 Oct; 109():45-55. PubMed ID: 29890296
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP.
Lu WJ; Chang NC; Jayakumar T; Liao JC; Lin MJ; Wang SH; Chou DS; Thomas PA; Sheu JR
Thromb Res; 2014 Dec; 134(6):1301-10. PubMed ID: 25294588
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibitory effects of the NO donor MAHMA/NONOate on human platelets.
Kobsar A; Simonis S; Klinker E; Koessler A; Kuhn S; Boeck M; Koessler J
Eur J Pharmacol; 2014 Jul; 735():169-76. PubMed ID: 24780647
[TBL] [Abstract][Full Text] [Related]
11. Potent antiplatelet activity of sesamol in an in vitro and in vivo model: pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase.
Chang CC; Lu WJ; Chiang CW; Jayakumar T; Ong ET; Hsiao G; Fong TH; Chou DS; Sheu JR
J Nutr Biochem; 2010 Dec; 21(12):1214-21. PubMed ID: 20015631
[TBL] [Abstract][Full Text] [Related]
12. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
13. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage.
Hsiao G; Lin KH; Chang Y; Chen TL; Tzu NH; Chou DS; Sheu JR
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1998-2004. PubMed ID: 15976325
[TBL] [Abstract][Full Text] [Related]
14. N1-(Quinolin-2-ylmethyl) butane-1, 4-diamine, a polyamine analog: inhibition of platelet aggregation mediated by an elevated VASP, and decreased MAPK phosphorylation.
Gao Y; Ji BS
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):476-85. PubMed ID: 24509331
[TBL] [Abstract][Full Text] [Related]
15. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
16. Guanosine exerts antiplatelet and antithrombotic properties through an adenosine-related cAMP-PKA signaling.
Fuentes F; Alarcón M; Badimon L; Fuentes M; Klotz KN; Vilahur G; Kachler S; Padró T; Palomo I; Fuentes E
Int J Cardiol; 2017 Dec; 248():294-300. PubMed ID: 28811090
[TBL] [Abstract][Full Text] [Related]
17. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Thromb Res; 2009 Jun; 124(2):199-207. PubMed ID: 19327818
[TBL] [Abstract][Full Text] [Related]
18. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies.
Aktas B; Utz A; Hoenig-Liedl P; Walter U; Geiger J
Stroke; 2003 Mar; 34(3):764-9. PubMed ID: 12624305
[TBL] [Abstract][Full Text] [Related]
19. Cordycepin-enriched WIB801C from Cordyceps militaris inhibits ADP-induced [Ca(2+)] i mobilization and fibrinogen binding via phosphorylation of IP 3R and VASP.
Lee DH; Kwon HW; Kim HH; Lim DH; Nam GS; Shin JH; Kim YY; Kim JL; Lee JJ; Kwon HK; Park HJ
Arch Pharm Res; 2015 Jan; 38(1):81-97. PubMed ID: 25001901
[TBL] [Abstract][Full Text] [Related]
20. The thrombin inhibitors hirudin and Refludan(®) activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets.
Kobsar A; Koessler J; Kehrer L; Gambaryan S; Walter U
Thromb Haemost; 2012 Mar; 107(3):521-9. PubMed ID: 22234363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
